Joaquim Bellmunt Molins

Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis

B. Escudier, Alain Ravaud, Sylvie Négrier et al. · Journal of Clinical Oncology · 2008 · 43 citations

Tumour Histology, Surgical Oncology, Avoren Trial +20

Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2^nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU)

Joaquim Bellmunt Molins, Hans von der Maase, Christine Théodore et al. · Journal of Clinical Oncology · 2008 · 28 citations

Urology, Genitourinary Cancer, Medicine +6

Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC)

E. Bajetta, Alain Ravaud, Sergio Bracarda et al. · Journal of Clinical Oncology · 2008 · 23 citations

Urology, Angiogenesis, Years Ifn+pl +13

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Joaquim Bellmunt Molins, Jesús García-Donás Jiménez, Begoña P. Valderrama et al. · Clinical Genitourinary Cancer · 2020 · 14 citations

Maja Study, Urology, Genitourinary Cancer +9

A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer

Joan Carles, Romà Bastus Piulats, Javier Martín‐Broto et al. · Clinical & Translational Oncology · 2005 · 12 citations

Urology, Oncology, Medicine +7